While genomic alterations in CLDN6 were merely observed in the TCGA GCT cohort, we could further show CLDN6 / CLDN6 being detectable on mRNA and protein level in GCT cell lines including cisplatin-resistant subclones (-R) derived from SEM (TCam-2), EC (2102EP, NCCIT, NT2/D1), CC (JAR, JEG-3, BeWo), and an EC-YST-intermediate (1411H) (Additional file 1: Fig. S1A; Fig. 1A, B). The gene discussed is CLDN6; the disease is granular cell tumor.